LEUKEMIAS

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

FDA issues third CRL for lower-dose dasatinib Dasynoc over manufacturing, not data, as Xspray races to resubmit amid PPI absorption benefits.

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib fits first line.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

Phase 3 Asian trial shows acalabrutinib sharply improves progression-free survival vs chlorambucil-rituximab in untreated, medically unfit CLL patients with favorable safety.

FDA orphan designation boosts enzomenib for ALL, as menin inhibitor trials show early responses and tolerable safety in relapsed leukemia.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

FDA granted RMAT designation to lasme-cel, a CD22-targeting allogeneic CAR-T, for R/R B-ALL, the first such therapy in a pivotal trial for this indication.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

FDA approves Cavhanza, a nilotinib orally disintegrating tablet for adult Ph+ CML, enabling use with PPIs/H2RAs and meals for easier dosing.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.